α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra and the formation of aggregates (Lewy bodies) in neurons. alpha-Synuclein is the major protein in Lewy bodies and rare mutations in alpha-synuclein cause early-onset PD. Consequently, alpha-synuclein is implicated in the pathogenesis of PD. Here, we have investigated the degradation pathways of alpha-synuclein, using a stable inducible PC12 cell model, where the expression of exogenous human wild-type, A30P, or A53T alpha-synuclein can be switched on and off. We have used a panel of inhibitors/stimulators of autophagy and proteasome function and followed alpha-synuclein degradation in these cells. We found that not only is alpha-synuclein degraded by the proteasome, but it is also degraded by autophagy. A role for autophagy was further supported by the presence of alpha-synuclein in organelles with the ultrastructural features of autophagic vesicles. Since rapamycin, a stimulator of autophagy, increased clearance of alpha-synuclein, it merits consideration as a potential therapeutic for Parkinsons disease, as it is designed for chronic use in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, mutant forms of synuclein and oligomers are dependent on the autophagy–lysosome pathway for their clearance4–6.”
From Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice (2018) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies suggest that α-synuclein is degraded by macroautophagy, chaperone-mediated autophagy, and the proteasome20–23.”
From Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration (2020) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Macroautophagy is a key pathway for the clearance of aggregate-prone cytosolic proteins.”
From Lithium induces autophagy by inhibiting inositol monophosphatase (2005) · cites this paper as Webb et al., 2003
In the citing paper
“Early evidence suggested roles for CMA and macroautophagy in degrading SNCA/α‐synuclein (Webb et al, 2003; Cuervo et al, 2004).”
From Autophagy in major human diseases (2021) · cites this paper as Webb et al, 2003
In the citing paper
“We previously showed that EGFP-HDQ74 is cleared by autophagy.”
From Lithium induces autophagy by inhibiting inositol monophosphatase (2005) · cites this paper as Webb et al., 2003
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Greene, L. A., & Tischler, A. S. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.7.2424 · Cited by 5,553
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
A Drosophila model of Parkinson's disease
Feany, M. B., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,118
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,571
Conway, K. A., Harper, J. D., & Lansbury, P. T. (1998) · Nature Medicine · doi:10.1038/3311 · Cited by 1,499
Research works printed but not linked: 2
- Furlong, R. A., Narain, Y., Rankin, J., Wyttenbach, A., and Rubinsztein, D. C. (2000) Biochem. J. 346, 577-581 · DOI · Paper page
- Biederbick, A., Kern, H. F., and Elsasser, H. P. (1995) Eur. J. Cell Biol. 66, 3-14
Cited by
Items 501–600 of 1,001
Recent progress and future directions of the research on nanoplastic-induced neurotoxicity
Han, S.-W., Choi, J., & Ryu, K. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.379016 · Cited by 83
“Aggregates of pathogenic proteins, such as amyloid β, tau, huntingtin, and α-synuclein, which are found in neurodegenerative diseases, are generated by the impairment of the ubiquitin-proteasome system or the autophagy-lysosome pathway (Webb et al., 2003; Piras et al., 2016; Croce and Yamamoto, 2019).”
BackgroundWong, V. K. W., Wu, A., Wang, J., Liu, L., & Law, B. Y. K. (2015) · Molecules · doi:10.3390/molecules20033496 · Cited by 83
“Some mutant proteins, such as A53T/A30P α-synuclein or huntingtin, are identified as substrates of autophagy and can be degraded by autophagy [2,6,8,34,36].”
BackgroundHigashi, S., Moore, D. J., Yamamoto, R., Minegishi, M., Sato, K., Togo, T., Katsuse, O., Uchikado, H., Furukawa, Y., Hino, H., et al. (2009) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e3181b44ed8 · Cited by 80
Interplay between Sumoylation and Phosphorylation for Protection against α-Synuclein Inclusions
Shahpasandzadeh, H., Popova, B., Kleinknecht, A., Fraser, P. E., Outeiro, T. F., & Braus, G. H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.559237 · Cited by 79
MicroRNA-7 facilitates the degradation of alpha-synuclein and its aggregates by promoting autophagy
Choi, D. C., Yoo, M., Kabaria, S., & Junn, E. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.05.009 · Cited by 81
Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts
Teil, M., Arotçarena, M.-L., Faggiani, E., Laferrière, F., Bézard, E., & Dehay, B. (2020) · Biomolecules · doi:10.3390/biom10030391 · Cited by 86
Evidence of Native α-Synuclein Conformers in the Human Brain
Gould, N. S., Mor, D. E., Lightfoot, R. T., Malkus, K. A., Giasson, B. I., & Ischiropoulos, H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.c113.538249 · Cited by 86
“The steady state levels of -synuclein are regulated by protein degradation pathways, including lysosomal and proteasomal removal (10, 11).”
BackgroundC-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson’s disease
McGlinchey, R. P., Lacy, S. M., Huffer, K., Tayebi, N., Sidransky, E., & Lee, J. C. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008930 · Cited by 83
“Mounting evidence supports the involvement of the lysosome and proteasome in -syn degradation (24, 25).”
BackgroundMechanisms of alpha-synuclein toxicity: An update and outlook
(2020) · Progress in Brain Research · doi:10.1016/bs.pbr.2019.10.005 · Cited by 75
Neuroprotective action of lithium in disorders of the central nervous system.
Chiu, C., & Chuang, D. (2011) · PubMed · doi:10.3969/j.issn.1672-7347.2011.06.001 · Cited by 87
Role of autophagy in the clearance of mutant huntingtin: A step towards therapy?
Ravikumar, B., & Rubinsztein, D. C. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.08.008 · Cited by 85
Self-citationCarra, S., Crippa, V., Rusmini, P., Boncoraglio, A., Minoia, M., Giorgetti, E., Kampinga, H. H., & Poletti, A. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.009 · Cited by 76
“…in MNDs and other neurodegenerative protein conformational diseases (Bjorkoy et al., 2006; Crippa et al., 2010a, 2010b; Iwata et al., 2005a, 2005b; Pankiv et al., 2007; Ravikumar et al., 2002, 2004, 2005, 2006; Ravikumar and Rubinsztein, 2004, 2006; Webb et al., 2003; Williams et al., 2006).”
Endoplasmic reticulum stress, an important factor in the development of Parkinson’s disease
Mou, Z., Yuan, Y., Zhang, Z., Song, L.-K., & Chen, N. (2020) · Toxicology Letters · doi:10.1016/j.toxlet.2020.01.019 · Cited by 79
Wu, G., Wang, X., Feng, X., Zhang, A., Li, J., Gu, K., Huang, J. A., Pang, S., Dong, H., Gao, H., et al. (2011) · Brain Research · doi:10.1016/j.brainres.2011.04.013 · Cited by 83
“Though both ubiquitin–proteasome and autophagy have been involved in α-syn degradation (Webb et al., 2003), recent findings in experimental models and PD patients indicate that both system might converge to formation autophagoproteasome, and α-syn is the primary target of autophagy (Ferrucci et…”
Alpha galactosidase A activity in Parkinson's disease
Alcalay, R. N., Wolf, P., Levy, O. A., Kang, U. J., Waters, C., Fahn, S., Ford, B., Kuo, S., Vanegas, N., Shah, H., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.01.012 · Cited by 81
“Since the lysosome is involved in the degradation of alpha-synuclein (Webb et al., 2003), it is hypothesized that lysosomal dysfunction may lead to alpha-synuclein accumulation, and subsequently to PD (Moors et al., 2016).”
BackgroundAutophagy in Astrocytes and its Implications in Neurodegeneration
Sung, K., & Jiménez-Sánchez, M. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.12.041 · Cited by 80
Prigione, A., Piazza, F., Brighina, L., Begni, B., Galbussera, A., DiFrancesco, J. C., Andreoni, S., Piolti, R., & Ferrarese, C. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.04.022 · Cited by 82
Zhang, S., Eitan, E., Wu, T.-Y., & Mattson, M. P. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.016 · Cited by 73
“Normally, α-synuclein is degraded in proteasomes and by autophagy in lysosomes (Cuervo et al., 2004; Mak et al., 2010; Snyder et al., 2003; Webb et al., 2003; Xilouri et al., 2013).”
BackgroundBussi, C., Peralta Ramos, J. M., Arroyo, D. S., Gallea, J. I., Ronchi, P., Kolovou, A., Wang, J. M., Florey, O., Celej, M. S., Schwab, Y., et al. (2018) · Journal of Cell Science · doi:10.1242/jcs.226241 · Cited by 74
Parkinson's disease: acid‐glucocerebrosidase activity and alpha‐synuclein clearance
Blanz, J., & Saftig, P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13517 · Cited by 71
Propagation of tau and α-synuclein in the brain: therapeutic potential of the glymphatic system
Lopes, D. M., Llewellyn, S. K., & Harrison, I. F. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00293-2 · Cited by 81
“Several studies have demonstrated that α-synuclein can be degraded by the ubiquitin proteasome system or by the autophagy– lysosomal pathway, and studies show that pharmacological inhibition of either of these pathways can result in α-synuclein aggregation [126, 128, 132, 143, 144].”
BackgroundPivtoraiko, V. N., Harrington, A. J., Mader, B. J., Luker, A. M., Caldwell, G. A., Caldwell, K. A., Roth, K. A., & Shacka, J. J. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06838.x · Cited by 72
Sala, G., Stefanoni, G., Arosio, A., Riva, C., Melchionda, L., Saracchi, E., Fermi, S., Brighina, L., & Ferrarese, C. (2013) · Brain Research · doi:10.1016/j.brainres.2013.12.017 · Cited by 77
“The assessment of the protein levels of MEF2D was used as an index of CMA activity, based on the knowledge that MEF2D degradation is entirely ascribable to CMA, differently from asyn, that is known to be degraded also by macroautophagy and ubiquitin–proteasome system (UPS) (Webb et al., 2003).”
Hsp70 molecular chaperones and Parkinson's disease
Witt, S. N. (2009) · Biopolymers · doi:10.1002/bip.21302 · Cited by 84
Winder‐Rhodes, S. E., Garcia‐Reitböck, P., Ban, M., Evans, J. R., Jacques, T. S., Kemppinen, A., Foltynie, T., Williams‐Gray, C. H., Chinnery, P. F., Hudson, G., et al. (2012) · Movement Disorders · doi:10.1002/mds.24029 · Cited by 75
“Proteolysis is performed by 2 major mechanisms both of which have been implicated in pathogenesis of PD: the ubiquitin-proteasome system and lysosomaldependent autophagy.(15) Disruption of either pathway may reduce clearance and therefore cause accumulation of aggregate-prone proteins such as a-synuclein.”
BackgroundWei, P., Zhang, L., Nethi, S. K., Barui, A. K., Lin, J., Zhou, W., Shen, Y., Man, N., Zhang, Y., Xu, J., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.024 · Cited by 76
“Earlier reports have shown the degradation of some long-lived aggregate-prone proteins, including mutant huntingtin [19], A53T andA30P through autophagic participation in vitro [20].”
Thelen, M., Daμμe, M., Schweizer, M., Hagel, C., Wong, A. M. S., Cooper, J. D., Braulke, T., & Galliciotti, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035493 · Cited by 72
Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson’s Disease
Siracusa, R., Paterniti, I., Cordaro, M., Crupi, R., Bruschetta, G., Campolo, M., Cuzzocrea, S., & Esposito, E. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0496-4 · Cited by 76
Regulation of amyloid precursor protein processing by its KFERQ motif
Park, J.-S., Kim, D.-H., & Yoon, S.-Y. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.6.212 · Cited by 69
“These proteins include tau, A, APP, -synuclein and huntingtin (14-19).”
BackgroundPark, H. J., Shin, J. Y., Kim, H. N., Oh, S. H., & Lee, P. H. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.028 · Cited by 75
Anandhan, A., Rodriguez-Rocha, H., Bohovych, I., Griggs, A. M., Zavala-Flores, L., Reyes-Reyes, E. M., Seravalli, J., Stanciu, L. A., Lee, J., Rochet, J.-C., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.11.018 · Cited by 71
Reduction of mutant huntingtin accumulation and toxicity by lysosomal cathepsins D and B in neurons
Liang, Q., Ouyang, X., Schneider, L., & Zhang, J. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-37 · Cited by 70
Wu, J.-Z., Ardah, M. T., Haikal, C., Svanbergsson, A., Diepenbroek, M., Vaikath, N. N., Li, W., Wang, Z., Outeiro, T. F., El‐Agnaf, O. M. A., et al. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0159-7 · Cited by 78
Kim, M. S., Ra, E. A., Kweon, S. H., Seo, B. A., Ko, H. S., Oh, Y., & Lee, G. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.05.015 · Cited by 78
Ubiquitin–proteasome system dysfunction in Parkinson’s disease: current evidence and controversies
Lim, K.-L. (2007) · Expert Review of Proteomics · doi:10.1586/14789450.4.6.769 · Cited by 71
Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Oczkowska, A., Kozubski, W. P., Lianeri, M., & Dorszewska, J. (2014) · Current Genomics · doi:10.2174/1389202914666131210205839 · Cited by 83
Song, W., Patel, A., Qureshi, H. Y., Han, D., Schipper, H. M., & Paudel, H. K. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06165.x · Cited by 78
Comber, J. D., Robinson, T. M., Siciliano, N. A., Snook, A. E., & Eisenlohr, L. C. (2011) · Journal of Virology · doi:10.1128/jvi.02122-10 · Cited by 79
Matsui, H., Sato, F., Sato, S., Koike, M., Taruno, Y., Saiki, S., Funayama, M., Ito, H., Taniguchi, Y., Uemura, N., et al. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.02.046 · Cited by 71
“Although soluble alpha-synuclein is degraded both during autophagy and by the proteasome, aggregated alpha-synuclein is degraded and cleared mainly via the autophagy–lysosome pathway [23].”
BackgroundKeeling, E., Lotery, A. J., Tumbarello, D. A., & Ratnayaka, J. A. (2018) · Cells · doi:10.3390/cells7020016 · Cited by 81
Erustes, A. G., D’Eletto, M., Guarache, G. C., Ureshino, R. P., Bincoletto, C., Pereira, G. J. S., Piacentini, M., & Smaili, S. S. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24952 · Cited by 74
Metformin's Mechanisms in Attenuating Hallmarks of Aging and Age-Related Disease
Cheng, F., Liu, Y.-L., Du, J., & Lin, J. (2022) · Aging and Disease · doi:10.14336/ad.2021.1213 · Cited by 87
Cartier, A. E., Ubhi, K., Spencer, B., Vazquez-Roque, R. A., Kosberg, K. A., Fourgeaud, L., Kanayson, P., Patrick, C., Rockenstein, E., Patrick, G. N., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034713 · Cited by 69
Proteolysis of α‐synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology
Sacino, A. N., Brooks, M. M., Chakrabarty, P., Saha, K., Khoshbouei, H., Golde, T. E., & Giasson, B. I. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13743 · Cited by 68
Wu, A., Wu, J., Wong, V. K. W., Zhu, Y. Z., Lo, A., Liu, L., & Law, B. Y. K. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.002 · Cited by 74
Chartier, S., & Duyckaerts, C. J. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2854-6 · Cited by 75
The ubiquitin–proteasome system and neurodegenerative disorders
Layfield, R., Lowe, J. S., & Bedford, L. (2005) · Essays in Biochemistry · doi:10.1042/eb0410157 · Cited by 78
Regulation of neuronal autophagy and the implications in neurodegenerative diseases
Cai, Q., & Ganesan, D. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105582 · Cited by 75
Clioquinol induces autophagy in cultured astrocytes and neurons by acting as a zinc ionophore
Park, M.-H., Lee, S.-J., Byun, H.-R., Kim, Y., Oh, Y. J., Koh, J., & Hwang, J. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.01.009 · Cited by 76
“A number of neurodegenerative diseases are associated with accumulation of abnormal protein aggregates (Ross and Poirier, 2004), suggesting an important role for aberrant autophagy in their pathogenesis (Cuervo et al., 2004; Ravikumar et al., 2002; Ravikumar et al., 2004;Webb et al., 2003).”
BackgroundFowler, A. J., Hebron, M., Missner, A. A., Wang, R., Gao, X., Kurd-Misto, B. T., Liu, X., & Moussa, C. E.-H. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0266-z · Cited by 68
Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinsons Disease
Rivero-Ríos, P., Madero-Pérez, Fernández, B., & Hilfiker, S. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666151030103027 · Cited by 69
“αsynuclein can be degraded by both the UPS as well as by autophagic-lysosomal pathways [16-18].”
Dopaminergic system and neurons: Role in multiple neurological diseases
Chen, H., Li, J., Huang, Z., Fan, X., Wang, X., Chen, X., Guo, H., Liu, H., Li, S., Yu, S., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110133 · Cited by 71
Akt as a Victim, Villain and Potential Hero in Parkinson’s Disease Pathophysiology and Treatment
Greene, L. A., Levy, O., & Malagelada, C. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9671-8 · Cited by 79
Mechanism and Regulation of Autophagy and Its Role in Neuronal Diseases
Hu, Z., Yang, B., Mo, X., & Xiao, H. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8921-4 · Cited by 74
Melquist, S., Craig, D. W., Huentelman, M. J., Crook, R., Pearson, J. V., Baker, M. C., Zismann, V., Gass, J. M., Adamson, J. L., Szelinger, S., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/513320 · Cited by 75
Phospholipase D1 regulates autophagic flux and clearance of α-synuclein aggregates
Bae, E.-J., Lee, H.-J., Jang, Y.-H., Michael, S., Masliah, E., Min, D. S., & Lee, S. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.30 · Cited by 69
Autophagic flux control in neurodegeneration: Progress and precision targeting—Where do we stand?
Lumkwana, D., du Toit, A., Kinnear, C. J., & Loos, B. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.006 · Cited by 75
“pharmacological agents, up-regulation of autophagy has been shown to reduce various types of aggregate-prone proteins such as mutant a-synuclein, mutant tau, poly A and poly Q expansions, as well as to decrease associated cell death in in vitro (Ravikumar et al., 2002; Webb et al., 2003; Berger et al., 2006) and in vi…”
InfluentialArylsulfatase A, a genetic modifier of Parkinson’s disease, is an α-synuclein chaperone
Lee, J. S., Kanai, K., Suzuki, M., Kim, W. S., Yoo, H. S., Fu, Y., Kim, D.-K., Jung, B. C., Choi, M.-S., Oh, K. W., et al. (2019) · Brain · doi:10.1093/brain/awz205 · Cited by 69
The Role of VPS35 in the Pathobiology of Parkinson’s Disease
Sassone, J., Reale, C., Dati, G., Regoni, M., Pellecchia, M. T., & Garavaglia, B. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00849-8 · Cited by 78
Su, M., Shi, J., Yang, Y., Li, J., Zhang, Y., Chen, J., Hu, L., & Liu, C. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07180.x · Cited by 79
Vekrellis, K., & Stefanis, L. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.674111 · Cited by 76
“Although we have not found evidence for accumulation of total a-Synuclein following proteasomal inhibition in the cellular systems that we have used [49-51], a-Synuclein does seem to be degraded by the proteasome in other experimental settings [52,53].”
BackgroundPhenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34
Robke, L., Laraia, L., Corrales, M. A. C., Konstantinidis, G., Muroi, M., Richters, A., Winzker, M., Engbring, T., Tomassi, S., Watanabe, N., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201703738 · Cited by 68
Luna, E., & Luk, K. C. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.10.023 · Cited by 67
Mangieri, L. R., Mader, B. J., Thomas, C. E., Taylor, C. A., Luker, A. M., Tse, T. E., Huisingh, C., & Shacka, J. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093257 · Cited by 68
Cytoplasmic Lipid Droplets: Rediscovery of an Old Structure as a Unique Platform
Fujimoto, T., & Ohsaki, Y. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1377.010 · Cited by 79
Meiling-Wesse, K., Barth, H., Voss, C., Eskelinen, E., Epple, U. D., & Thumm, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401066200 · Cited by 76
Trifluoperazine rescues human dopaminergic cells from wild-type α-synuclein-induced toxicity
Höllerhage, M., Goebel, J. N., de Andrade, A., Hildebrandt, T., Dolga, A. M., Culmsee, C., Oertel, W. H., Hengerer, B., & Höglinger, G. U. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.027 · Cited by 71
“Besides the debate how alpha-synuclein influences autophagy, there is also a general debate if activation of autophagy would be protective or harmful in the context of a synucleinopathy: Some reports showed a protection of neuronal cells by autophagy in different models (Dadakhujaev et al., 2010; Fleming et al., 2011;…”
BackgroundTherapeutic induction of autophagy to modulate neurodegenerative disease progression
Hochfeld, W. E., Lee, S., & Rubinsztein, D. C. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.189 · Cited by 64
Self-citationXu, Y., Tian, C., Wang, S.-B., Xie, W.-L., Guo, Y., Zhang, J., Shi, Q., Chen, C., & Dong, X. (2012) · Autophagy · doi:10.4161/auto.21482 · Cited by 68
Kragh, C. L., Ubhi, K., Wyss‐Corey, T., & Masliah, E. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00545.x · Cited by 65
Autophagy in neuroinflammatory diseases
Muller, S., Brun, S., René, F., Seze, J. D., Loeffler, J., & Jeltsch‐David, H. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.05.015 · Cited by 68
Autophagy in aging and in neurodegenerative disorders
Rajawat, Y. S., & Bossis, I. (2008) · HORMONES · doi:10.14310/horm.2002.1111037 · Cited by 79
“It has been hypothesized that when macroautophagy is induced to compensate for the CMA defect, impaired autophagosome-lysosome fusion and incomplete lysosome acidification occur.(116)”
BackgroundPrasanth, M. I., Sivamaruthi, B. S., Cheong, C. S. Y., Verma, K., Tencomnao, T., Brimson, J. M., & Prasansuklab, A. (2024) · Antioxidants · doi:10.3390/antiox13050606 · Cited by 71
“As the autophagy–lysosome pathway contributes to the clearance of defective/misfolded proteins, lysosomal dysfunction causes the aggregation and accumulation of α -synuclein [145].”
BackgroundBai, X., Wey, M. C.-Y., Fernandez, E., Hart, M. J., Gelfond, J., Bokov, A. F., Rani, S., & Strong, R. (2015) · Pathobiology of Aging & Age-related Diseases · doi:10.3402/pba.v5.28743 · Cited by 61
“RAPA reduces paraquat toxicity in vivo (2), rotenone toxicity in vitro and the accumulation of a-synuclein and neurodegenerative phenotype in a-synuclein overexpressing cells (5,6,24) and mice (7) by inducting autophagy (27).”
BackgroundThe role of autophagy in endoplasmic reticulum stress-induced pancreatic β cell death
Yin, J.-J., Li, Y.-B., Wang, Y., Liu, G.-D., Wang, J., Zhu, X.-O., & Pan, S.-H. (2012) · Autophagy · doi:10.4161/auto.8.2.18807 · Cited by 65
Garcia-Garcia, A., Anandhan, A., Burns, M., Chen, H., Zhou, Y., & Franco, R. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft188 · Cited by 67
“Autophagy and chaperone-mediated autophagy have been proposed to prevent α-synuclein accumulation (Cuervo et al., 2004; Webb et al., 2003), whereas Parkin and PTEN-induced putative kinase 1 have been shown to regulate mitochondrial targeted autophagy (mitophagy) (Dagda et al.”
BackgroundNtsapi, C., & Loos, B. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.07.014 · Cited by 71
Ottolini, D., Calí, T., Szabó, I., & Brini, M. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0201 · Cited by 75
Overexpression of α‐synuclein in an astrocyte cell line promotes autophagy inhibition and apoptosis
Erustes, A. G., Stefani, F. Y., Terashima, J. Y., Stilhano, R. S., Monteforte, P. T., da Silva Pereira, G. J., Han, S. W., Calgarotto, A. K., Hsu, Y., Ureshino, R. P., et al. (2018) · Journal of Neuroscience Research · doi:10.1002/jnr.24092 · Cited by 64
Yoon, Y.-S., Cho, E.-D., Ahn, W. J., Lee, K. W., Lee, S., & Lee, H.-J. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.501 · Cited by 68
Can autophagy protect against neurodegeneration caused by aggregate-prone proteins?
Ravikumar, B., & Rubinsztein, D. C. (2004) · NeuroReport · doi:10.1097/00001756-200411150-00001 · Cited by 63
“We observed that while all forms of a-synuclein are cleared by autophagy, perturbations in the autophagic pathway had the greatest impact on the clearance of the A53T compared to A30P or wild-type a-synuclein, consistent with the tendency of A53T to aggregate more readily than the other forms [20].”
BackgroundResultSelf-citationBae, N.-Y., Ahn, T.-W., Chung, S., Oh, M. S., Ko, H., Oh, H., Park, G., & Yang, H. O. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.12.016 · Cited by 69
Alzheimer’s disease and the autophagic-lysosomal system
Chung, K. M., Hernández, N., Sproul, A. A., & Yu, W. H. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.05.017 · Cited by 63
Fan, R. Z., Guo, M., Luo, S., Cui, M., & Tieu, K. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0821-4 · Cited by 64
Manipulation of Death Pathways in Desmin-Related Cardiomyopathy
Maloyan, A., Sayegh, J., Osinska, H., Chua, B. H. L., & Robbins, J. (2010) · Circulation Research · doi:10.1161/circresaha.109.212639 · Cited by 63
Petibone, D. M., Majeed, W., & Casciano, D. A. (2016) · Journal of Applied Toxicology · doi:10.1002/jat.3393 · Cited by 69
“Elevated α-synuclein levels are a consequence of alterations in the ubiquitin–proteasome system or the autophagy–lysosomal pathway that obstruct α-synuclein degradation (Cuervo et al., 2004; Webb et al., 2003).”
BackgroundMallucci, G. R., Klenerman, D., & Rubinsztein, D. C. (2020) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-040320-120625 · Cited by 62
Self-citationHigashi, S., Moore, D. J., Minegishi, M., Kasanuki, K., Fujishiro, H., Kabuta, T., Togo, T., Katsuse, O., Uchikado, H., Furukawa, Y., et al. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318211c86a · Cited by 61
Synaptic dysfunction in genetic models of Parkinson's disease: A role for autophagy?
Plowey, E. D., & Chu, C. T. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.011 · Cited by 59
“Autophagy contributes to the degradation of α-synuclein (Webb et al., 2003; Yu et al., 2009), providing another avenue through which autophagy may impact synaptic function.”
Wei, J., Fujita, M., Nakai, M., Waragai, M., Sekigawa, A., Sugama, S., Takenouchi, T., Masliah, E., & Hashimoto, M. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080680 · Cited by 65
“A recent study shows that the autophagy-lysosome pathway may play a central role in the degradation of -syn.(45) Because PDMP treatment resulted in suppression of autophagy, it was predicted that accumulation of syn proteins may be stimulated in our cellular model of synucleinopathies.”
Yang, L., Zhang, J., Zheng, K., Shen, H., & Chen, X. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt091 · Cited by 62
Filamentous Aggregates Are Fragmented by the Proteasome Holoenzyme
Cliffe, R., Sang, J. C., Kundel, F., Finley, D. J., Klenerman, D., & Ye, Y. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.096 · Cited by 64
“Aggregate degradation via both the proteasomal and the lysosomal systems has been described in the literature (e.g., Wang and Mandelkow, 2012; Webb et al., 2003).”
MethodPathological Proteins in Parkinson's Disease: Focus on the Proteasome
Snyder, H. M., & Wolozin, B. L. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:3:425 · Cited by 70
Rousseaux, M. W. C., Vázquez-Vélez, G. E., Al-Ramahi, I., Jeong, H.-H., Bajić, A., Revelli, J.-P., Ye, H., Phan, E. T., Deger, J. M., Perez, A. M., et al. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.0254-18.2018 · Cited by 61
“Additionally, KDELRs have been reported to regulate autophagy, a well-known mediator -Syn clearance (Webb et al., 2003).”
BackgroundStrategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Haas, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110986 · Cited by 70
Unni, V. K., Weissman, T. A., Rockenstein, E., Masliah, E., McLean, P. J., & Hyman, B. T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010589 · Cited by 62
Poulose, S. M., Bielinski, D. F., & Shukitt‐Hale, B. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.06.009 · Cited by 66
“In animal studies, activation of autophagy in brain via inhibition of mTOR activation has been implicated in the prevention and breakdown of amyloid accumulation, clearance of huntingtin and α-synuclein [32–37].”
BackgroundAlvarez‐Castelao, B., Goethals, M., Vandekerckhove, J. S., & Castaño, J. G. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.11.018 · Cited by 64
Blennow, K., Biscetti, L., Eusebi, P., & Parnetti, L. (2016) · Movement Disorders · doi:10.1002/mds.26656 · Cited by 66
“Analogously, mutations of the NAGLU gene, encoding for a-N acetylglucosaminidase, are linked to an increased risk of developing PD and to Lewy body formation.(144) As a result of these findings, some researchers have investigated the measurements of lysosomal enzyme activities in CSF as possible biomarkers in PD.”
BackgroundLysosomal trafficking defects link Parkinson's disease with Gaucher's disease
Wong, Y. C., & Krainc, D. (2016) · Movement Disorders · doi:10.1002/mds.26802 · Cited by 59
Metadata
- Authors
- Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C.
- Affiliations
- Addenbrooke's Hospital (GB)
- University of Cambridge (GB)
- Corresponding author
- Rubinsztein, David C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-07
- Volume
- 278
- Issue
- 27
- Pages
- 25009-25013
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2157535220
- Cited by
- 1,429
- References
- 37
- Citations by year
- 2026: 36 · 2025: 41 · 2024: 76 · 2023: 50 · 2022: 68 · 2021: 71 · 2020: 83 · 2019: 85 · 2018: 77 · 2017: 62 · 2016: 65 · 2015: 65 · 2014: 75 · 2013: 79 · 2012: 95
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6305 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Parkinson's UK
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- alpha-synuclein, Parkinson's disease, autophagy, proteasome, protein degradation, Lewy bodies, A30P mutation, A53T mutation, PC12 cells, rapamycin, autophagic vesicles, dopaminergic neurons
- MeSH terms
- Animals, Antibiotics, Antineoplastic, Autophagy, Cysteine Endopeptidases, Humans, Multienzyme Complexes, Nerve Tissue Proteins, PC12 Cells, Sirolimus, Proteasome Endopeptidase Complex, Rats, Synucleins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.